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Plasma Xanthine Oxidase Activity in Patients With Adult 
Respiratory Distress Syndrome 
Cyril M. Grum, Richard A. Ragsdale, Loren H. Ketai, and Richard H. Simon 
Oxygen metabolites have been implicated in the 
pathogenesis of various types of acute tissue injury. 
One biologic source of oxygen metabolites is the 
reaction catalyzed by the enzyme xanthine oxidase. 
Because we previously demonstrated that the sub- 
strates for xanthine oxidase (hypoxanthine and xan- 
thine) are elevated in the plasma of critically il l 
patients, we questioned whether the enzyme itself 
might also be present. We therefore measured 
hypoxanthine concentration and xanthine oxidase 
activity in the plasma of 15 patients with ARDS and 
in 13 non-ARDS critically il l patients. Plasma xan- 
T HE MECHANISMS of injury in the adult respiratory distress syndrome (ARDS) 
have been the subject of considerable interest. 
One category of mediators implicated in the 
pathogenesis of acute lung injury are the toxic 
oxygen metabolites.ld In addition to evidence 
from animal models of ARDS, there is now 
evidence that oxygen metabolites are present in 
human ARDS,’ and can alter lung constituents.* 
Oxygen metabolites can be generated from many 
sources and are thought to play a role in some 
forms of ischemic injury.g,la An additional source 
of oxygen metabolites is stimulated neutrophils, 
which have been implicated as an agent of alveo- 
lar injury in ARDS.4-6,“3’2 Whether additional 
sources of oxygen metabolites participate in 
human ARDS is not certain. 
The enzyme xanthine oxidase produces the 
oxygen metabolites superoxide anion and hydro- 
gen peroxide when it oxidizes hypoxanthine or 
xanthine to uric acid.g3’0313%‘4 These oxygen 
metabolites can then form a variety of additional 
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thine oxidase activity in our ARDS group 
(1.514 i 975 mlU/L, mean + SE) was higher than 
that seen in the non-ARDS group (17 + 4 mlU/L, 
P 5 .OS). Plasma hypoxanthine was elevated in both 
groups, and there was no difference between the 
ARDS and non-ARDS groups (22.0 + 9.2 wmol/L and 
11.8 + 4.3 Fmol/L, respectively). The presence of 
both circulating xanthine oxidase and its substrate 
demonstrates the potential for intravascular oxygen 
metabolite production. These toxic products may 
then cause tissue injury in ARDS. 
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toxic compounds.10~‘5 When xanthine oxidase and 
xanthine are instilled intratracheally into rat 
lungs or perfused through the vasculature of 
isolated rabbit lungs, oxygen metabolites are 
generated and acute high permeability lung 
edema occurs.16-1g In the cat intestine and dog 
heart, ischemia activates endogenous xanthine 
oxidase, which generates toxic oxygen metabo- 
lites and causes acute tissue injury.g3’4*20 We have 
previously demonstrated increased concentra- 
tions of hypoxanthine and xanthine in the plasma 
of critically ill patients including those with 
ARDS.” Although xanthine oxidase is normally 
undetectable in human plasma,22323 we ques- 
tioned whether it may be present in ARDS. 
Because of the ability of xanthine oxidase to 
generate toxic oxygen metabolites and the sus- 
pected role of these metabolites in ARDS, we 
measured the activity of endogenous xanthine 
oxidase in the plasma of ARDS patients. 
MATERIALS AND METHODS 
Patients 
We studied 15 patients with ARDS. Our diagnostic crite- 
ria for ARDS were modified from Fowler et a1.r4 Acute 
respiratory failure requiring mechanical ventilation, diffuse 
bilateral alveolar infiltrates on chest roentgenogram, require- 
ment of an F,O, of greater than 0.6 to maintain a PaO, above 
60 torr, and the absence of left ventricular failure (pulmonary 
artery wedge pressure 518). Non-ARDS patients who had 
acute illnesses requiring admission to an intensive care unit 
were studied concurrently. All non-ARDS patients had no 
evidence of diffuse lung injury but required supplementary 
oxygen and an arterial catheter for management. No patient 
was receiving allopurinol at the time of study. This study was 
approved by the Human Subject Review Committee of the 
University of Michigan. 
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Sample Collection 
Ten milliliters of arterial blood was collected into pre- 
chilled tubes containing heparin, erythro-9-(2 hydroxy-3 
nonyl) adenine hydrochloride, and dipyridamole.21 The latter 
two chemicals were necessary to prevent purine degradation 
and transcellular fluxes of adenosine. The sample was imme- 
diately centrifuged at 1,500 g, 4 OC for ten minutes, and the 
plasma separated and frozen at -70 OC until analysis. The 
ARDS patients were studied as soon as possible after they 
met diagnostic criteria and always within 24 hours of devel- 
oping the syndrome. 
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Table 1. Characteristics of Patient Populations 
We measured xanthine oxidase activity by monitoring the 
rate of conversion of %hypoxanthine to 14C-xanthine and 
‘%-uric acid, modifying the technique of Sinclair and Fox.” 
Ten microliters of plasma was added to 30 pL of 0.05 mol/L 
potassium phosphate buffer, pH 8.5, and 10 rL of %- 
hypoxanthine (56 mCi/mmole, ICN). The final concentra- 
tion of 14C-hypoxanthine was 95 pmol/L. The sample was 
then incubated in a shaking water bath at 37 “C for 60 
minutes. The reaction was stopped by the addition of 10 hL of 
1.7 mol/L perchloric acid. After a ten-minute centrifugation 
at 1,500 g, 5 @L of supernatant was spotted on 3 mm 
Whatman chromatography paper. Forty microliters of an 
internal marker consisting of a mixture of 10 mmol/L 
hypoxanthine, xanthine, and uric acid in 0.05 mol/L potas- 
sium phosphate buffer, pH 8.5, was also spotted on the 
chromatography paper. The compounds were separated using 
high voltage electrophoresis (Gilson) in 50 mmol/L sodium 
borate buffer, pH 8.9, at 3.5 kV for 35 minutes. After drying, 
the compounds were identified under ultraviolet light and the 
radioactivity determined by scintillation counter. The activ- 
ity of xanthine oxidase is expressed as mIU/L plasma. One 
international unit of xanthine oxidase will metabolize one 
micromole of hypoxanthine per minute. 
Plasma Hypoxanthine 
Plasma hypoxanthine concentration was determined by 
high pressure liquid chromatography using an acetylnitrile 
gradient as previously described.*’ In brief, plasma was 
deproteinized by filtration and then divided into two aliquots, 
one of which was treated with specific enzymes to convert all 
intermediate products of adenosine triphosphate (ATP) deg- 
radation to uric acid. Loss of the peak eluting at the same 
time as authentic hypoxanthine in the enzyme treated sample 
confirmed its identity as hypoxanthine. By comparing the 
peak areas to known calibration standards, the plasma hypo- 
xanthine concentration was obtained. 
Statistical Analysis 
Group data was expressed as mean f SE. Data from 
ARDS and non-ARDS groups were compared by the Wil- 
coxon nonpaired rank sum test. Probability values less than 
.05 were considered significant. 
RESULTS 
The characteristics of the ARDS and non- 
ARDS patients are shown in Table 1. There were 
ARDS NowARDS 
n 15 
Age (yr) t SE 46 + 3 
F,O, + SE 0.02 + 0.05 
Associated di- 
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*Some patients had more than one associated diagnosis. 
five females in each group. There was evidence of 
pulmonary dysfunction in both groups as demon- 
strated by the need for supplemental oxygen. 
There was no difference between the groups in 
cardiac output, systolic blood pressure, or serum 
creatinine. The ARDS group had a lower arterial 
pH (7.35 f 0.02) than the non-ARDS group 
(7.42 rt .02, P 5 .OS). 
Plasma xanthine oxidase activity of the two 
groups is presented in Fig 1. The mean xanthine 
oxidase activity in the ARDS group 
(1,514 f 975 mIU/L) was higher than that seen 
in the non-ARDS group (17 + 4 mIU/L, 
PI .05). Eight of fifteen patients with ARDS 
had plasma xanthine oxidase activities higher 
than any of the non-ARDS group, (range, 94 to 
14,000 mIU/L). The three patients with the 
highest levels of circulating xanthine oxidase :had 
elevated liver function tests (serum glutamic 
oxaloacetic transaminase, alkaline phosphatase, 
bilirubin) suggesting that severe ischemic liver 
damage might have been a source of the xanthine 
oxidase. Excluding these three patients, levels of 
abnormal liver function tests did not correlate 
with serum xanthine oxidase activity in either 
group. Of the two patients in the non-ARDS 
group with the highest levels of xanthine oxidase 
activity (39 and 61 mIU/L), one had elevated 
liver function tests and the other did not. 
Plasma levels of hypoxanthine are shown in 
Fig 2. The plasma level of hypoxanthine in the 
ARDS group (22.0 f 9.2 hmol/L) was not dif- 
ferent from that seen in our non-ARDS group 
(11.8 k 4.3 gmol/L). However, the levels in both 
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Fig 2. Plasma hypoxanthine concentrations in ARDS 
patients and non-ARDS patients. Mean -f SE values are 
presented. Although there was no difference between the 
ARDS (22.0 + 9.2 pmol/L) and non-ARDS groups 
(I 1.8 + 4.3 Amol/L), both of these values are higher than 
that found in a group of 14 normal volunteers (1.1 f 0.1 
/.rmol/L), which we have published previously.*’ 
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Fig. 1. Plasma xanthine oxidase activity in the ARDS 
patient group (n = 15) and the non-ARDS patient group 
In = 13). The mean + SE activity in the ARDS group 
(1.514 + 975 mllJ/L) was significantly higher than in the 
non-ARDS group (I 7 k 4 mlL/L, P 5 .05L 
groups were much higher than those of the 14 
healthy volunteers (1 .l f 0.1 pmol/L) that we 
have previously reported.26 There was no correla- 
tion between the plasma level of hypoxanthine 
and the activity of xanthine oxidase in either 
group. No correlation was seen between xanthine 
oxidase levels and measurements of lung dys- 
function within the ARDS group, but the sizes of 
the subgroups were small. 
DISCUSSION 
The mechanism of lung injury in ARDS is 
probably multifactorial. Animal studies have 
suggested that toxic oxygen metabolites may be 
one important mechanism of acute tissue dam- 
age.‘” Oxygen metabolites may be generated 
from many sources including the metabolism of 
hypoxanthine by the enzyme xanthine oxi- 
dase.g5’0 Exogenous administration of this 
enzyme and substrate either intratracheally or 
intravascularly has caused acute permeability 
lung injury in animal models.‘6m’g Furthermore, 
there is evidence suggesting that endogenous 
enzyme and substrate may participate in acute 
tissue injury in other organ systems such as the 
dog and rat myocardium and cat intestine.9314720 
Circulating xanthine oxidase is normally unde- 
tectable in human serum.22323 Levels of plasma 
xanthine oxidase found in this study are of 
comparable magnitude to those which have 
caused lung damage in experimental models.‘7*27 
The present study demonstrates that some 
patients with ARDS have elevation of both 
hypoxanthine and xanthine oxidase activity. We 
therefore have documented the presence of an 
enzyme that can catalyze the production of toxic 
oxygen metabolites together with its substrate in 
patients with ARDS. Of note, in a study of infant 
respiratory distress syndrome, allopurinol (an 
inhibitor of xanthine oxidase) caused decreased 
infant mortality when compared to placebo.28 
Although infant respiratory distress syndrome 
differs from ARDS in its initiating factors, after 
it is established it shares many characteristics 
with ARDS.2g 
ARDS is a systemic disorder with evidence of 
diffuse capillary damage.30 Plasma xanthine oxi- 
dase might cause predominant lung injury if the 
liver is the site of its release since the alveolar 
capillaries are the first capillary bed exposed to 
its activity. Alternatively, the high oxygen con- 
centration of the alveolar environment may pre- 
dispose to injury by providing higher concentra- 
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tions of the other substrate for xanthine oxidase, 
ie, oxygen. Saugstad has reported the occurrence 
of lung injury in neonatal rats (which have 
endogenous xanthine oxidase activity in their 
lungs) when he ventilated animals with 100% 
oxygen and perfused them with hypoxanthine.16 
Injury did not occur when room air ventilation 
and glucose infusion were used. 
xanthine release exceeds both uptake and metab- 
olism. 
The presence of multiorgan failure in many 
patients with ARDS suggests the presence of a 
circulating toxic agent. We speculate that circu- 
lating hypoxanthine and xanthine oxidase may 
be one of the contributors to the diffuse tissue 
injury seen in human ARDS. The source of 
circulating xanthine oxidase in our patients is 
unclear. In humans, two organs known to be rich 
in xanthine oxidase are the liver and small intes- 
tine.** This fact, together with our finding that 
the highest levels of xanthine oxidase activity 
were in patients with severe liver injury, suggests 
a hepatic source of the circulating enzyme in 
some patients. Xanthine oxidase has been 
reported to be present in the lung of some animal 
species, and may be released from the lung into 
the systemic circulation in the dog.23 Whether 
xanthine oxidase is present in human lung or is 
released into the circulation from the lung has 
not been tested. Ischemia has been shown to be a 
potent activator of xanthine oxidase.g We suspect 
that the lower pH in our ARDS group was most 
likely due to lactic acid production by ischemic/ 
hypoxic tissues. This then may be another source 
of circulating xanthine oxidase. 
We could not detect elevations of circulating 
xanthine oxidase in all our patients with ARDS. 
This may be due to the likelihood that there are 
multiple causes of ARDS.32 It is possible that 
xanthine oxidase release is part of the pathologic 
process of some but not all conditions associated 
with ARDS. Because xanthine oxidase in 
humans is concentrated in liver and small intes- 
tine, we speculate that a risk factor for increased 
plasma levels of xanthine oxidase may be 
patients with ischemic insults to these organs. 
Our finding of increased liver dysfunction and 
the lower systemic pH in patients with elevated 
xanthine oxidase supports this speculation. Other 
factors causing elevated plasma xanthine oxidase 
remain to be elucidated. Alternatively, circulat- 
ing xanthine oxidase may have been initially 
present but subsequently bound or cleared by 
antibodies to xanthine oxidase. The presence of 
relatively high levels of antixanthine oxidase 
antibodies in the serum of normal human volun- 
teers has been documented.33 The role of these 
antibodies in disease states and their possible 
protective effects, however, have not been delin- 
eated. 
We suggest that the elevated hypoxanthine 
levels in these patients is most likely due to tissue 
hypoperfusion and ATP breakdown. These levels 
are comparable to that previously described in 
critically ill patients.*’ Recent work by Ketai et 
al has suggested that the kidney, diaphragm, and 
liver tissue beds are the highest sources of hypo- 
xanthine release.3’ The elevated concentration of 
hypoxanthine in our patients implies that hypo- 
In summary, we have shown high levels of 
circulating xanthine oxidase activity in some 
patients with ARDS but not in non-ARDS criti- 
cally ill patients. This activity, together ,with 
elevated circulating substrate, provides the 
opportunity for the generation of toxic oxygen 
metabolites in human ARDS. Whether toxic 
oxygen metabolites are, in fact, generated by this 
mechanism and whether inhibition of xanthine 
oxidase will prove beneficial in this setting, 
remains to be determined. 
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